Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 9/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34467674 | 0.92 | NPSR1 (0.47) | TDP1NPSR1MAPTKMT2AKDM4E | |
| SCHEMBL34467686 | 0.91 | TDP1 (0.43) | P2RY2TDP1NPSR1MAPTKMT2A | |
| SCHEMBL34467667 | 0.83 | TDP1 (0.42) | TDP1NPSR1MAPTKMT2AKDM4E | |
| SCHEMBL34467670 | 0.83 | TDP1 (0.42) | P2RY2TDP1NPSR1MAPTKMT2A | |
| SCHEMBL34467680 | 0.83 | CTSK (0.45) | P2RY2TDP1NPSR1MAPTKMT2A | |
| SCHEMBL34467659 | 0.82 | TDP1 (0.48) | P2RY2TDP1NPSR1MAPTKMT2A | |
| SCHEMBL34467681 | 0.82 | TDP1 (0.48) | P2RY2TDP1NPSR1MAPTKMT2A | |
| SCHEMBL31300272 | 0.78 | DRD2 (0.36) | TDP1KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL34467683 | 0.75 | LTA4H (0.37) | ALDH1A1 | |
| SCHEMBL25342225 | 0.73 | TDP1 (0.54) | P2RY2TDP1NPSR1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117274-A1 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2026-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117274-A1 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | PTMS, PSMG3, PSMB3 | P2RY2 4875/4885TDP1 2643/4885NPSR1 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.